Hautveränderungen bei malignen hämatologischen Erkrankungen

Schmid‐Wendtner, Monika‐Hildegard; Hornung, Thorsten; Meurer, Michaela; Wendtner, C. M.

doi:10.1007/s00105-015-3650-9

Cited by 7 publications

(2 citation statements)

References 20 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a prevailing sentiment that targeting the cytokine milieu of the tumour microenvironment may increase the efficacy of tumour-directed therapies. For example, experimental evidence supports targeting the IL-1-related pathways to augment the efficacy of tyrosine kinase inhibitors in patients with chronic myeloid leukaemia [ 6 ]. Likewise, IL-17 has been shown to support the growth of tumoural cells in Hodgkin’s lymphoma and B-cell chronic lymphatic leukaemia, and promote resistance to chemotherapy in patients with acute leukaemia, suggesting that patients would likely benefit from IL-17-directed therapies [ 19 – 21 ].…”

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

“…Patients with HMs can experience a broad range of dermatological manifestations. Comorbid diseases affecting the skin are often associated with a significant impairment on the quality of life and, more rarely, with an increased risk of death [ 4 – 6 ]. Dermatological manifestations associated with HMs can be divided into specific and non-specific.…”

Section: Haematological Malignancies As a Trigger For Skin Autoimmunimentioning

confidence: 99%

See 1 more Smart Citation

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

Haematological malignancies induce important alterations of the immune system, which account for the high frequency of autoimmune complications observed in patients. Cutaneous immune-mediated diseases associated with haematological malignancies encompass a heterogeneous group of dermatoses, including, among others, neutrophilic and eosinophilic dermatoses, autoantibody-mediated skin diseases, vasculitis and granulomatous dermatoses. Some of these diseases, such as paraneoplastic pemphigus, are associated with an increased risk of death; others, such as eosinophilic dermatoses of haematological malignancies, run a benign clinical course but portend a significant negative impairment on a patient's quality of life. In rare cases, the skin eruption reflects immunological alterations associated with an unfavourable prognosis of the associated haematological disorder. Therapeutic management of immune-mediated skin diseases in patients with haematological malignancies is often challenging. Systemic corticosteroids and immunosuppressive drugs are considered frontline therapies but may considerably augment the risk of serious infections. Indeed, developing a specific targeted therapeutic approach is of crucial importance for this particularly fragile patient population. This review provides an up-to-date overview on the immune-mediated skin diseases most frequently encountered by patients with onco-haematological disorders, discussing new pathogenic advances and therapeutic options on the horizon.

show abstract

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

Section: Haematological Malignancies As a Trigger For Skin Autoimmunimentioning

confidence: 99%

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

show abstract

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department

Merlo

Cozzani

Canale

et al. 2018

Hematological Oncology

View full text Add to dashboard Cite

In recent years, dermatologic manifestations in oncohematologic patients have become more common. The aim of our study was to determine the incidence and heterogeneity of skin manifestations in patients followed at our Hematology Department. This observational monocentrical study was conducted on 60 patients. We divided the observed conditions in exanthematous, purpuric, vesicular‐bullous, papulonodular, urticarial, and eczematous manifestations. Moreover, all lesions were classified according to pathogenesis, in (a) specific skin manifestations, caused by neoplastic skin infiltration; (b) immune‐mediated manifestations, based on immunological mechanisms; and (c) skin lesions due to immunodeficiency. Altogether, 73 clinical manifestations were reported. Specific manifestations (a) were detected in 15.1% of the cases, mainly with papulonodular appearance. Immune‐mediated manifestations (b) were found in 37 cases (50.7%), particularly with eczematous or exanthematous appearance, and leukemia was the malignancy most frequently reported in these patients. Eventually, lesions due to immunosuppression (c) were reported in 34.2% of the cases. They were represented by infections and cutaneous malignancies, and usually manifested with papulonodular lesions. Skin lesions in oncohematologic patients are a common event. A multidisciplinary approach based on the collaboration between the hematologist and the dermatologist is crucial to achieve a proper diagnosis, and correctly manage these manifestations.

show abstract

Hautveränderungen bei Leukämien

Ugurel

Becker²

2018

Braun-Falco’s Dermatologie, Venerologie Und Allergologie

View full text Add to dashboard Cite

Hautveränderungen bei malignen hämatologischen Erkrankungen

Cited by 7 publications

References 20 publications

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department

Hautveränderungen bei Leukämien

Contact Info

Product

Resources

About